Westchester-based biotechnology company ranked
in top 10 for fifth consecutive year
Biotechnology leader Acorda Therapeutics, Inc. (Nasdaq:ACOR) has
been named one of the best companies to work for in New York, based
on an independent survey by the Best Companies Group (BCG). Acorda
was named to the list for the fifth consecutive year.
Acorda was ranked third among this year’s list of large
employers, defined as employing more than 250 people. The rankings
are determined by feedback from employees about company culture,
benefits and overall job satisfaction.
“It’s gratifying to be recognized as one of the best places to
work in New York, especially when that recognition is based on
feedback from Acorda’s own associates,” said Ron Cohen, M.D.,
Acorda’s President and CEO. “A key contributor to our success is
the company’s vibrant culture, which emphasizes teamwork, integrity
and fun. Acordans also share a deeply held sense of mission, to
develop life-changing therapies for people with neurological
disorders. These features make Acorda a great place to build a
career.”
“The dedication of our associates is exemplified by their having
brought AMPYRA to market; AMPYRA is a unique medication that
improves walking for people with multiple sclerosis. This spirit of
innovation has also allowed us to build one of the most exciting
neurology pipelines in the industry, with the potential to improve
the lives of people with conditions such as Parkinson’s disease,
stroke, epilepsy, multiple sclerosis and heart failure,” continued
Cohen.
The Best Places to Work survey was conducted by BCG, an
independent company that manages Best Places to Work programs on
state, regional and national levels. The award is a partnership of
the New York State Society for Human Resource Management, the
Business Council of New York, BCG and Journal Multimedia
Corporation.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a
biotechnology company focused on developing therapies that restore
function and improve the lives of people with neurological
disorders.
Acorda markets three FDA-approved therapies, including
AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a
treatment to improve walking in patients with multiple sclerosis
(MS), as demonstrated by an increase in walking speed. The Company
has one of the leading pipelines in the industry of novel
neurological therapies. Acorda is currently developing a number of
clinical and preclinical stage therapies. This pipeline addresses a
range of disorders including post-stroke walking deficits,
Parkinson’s disease, epilepsy, neuropathic pain, heart failure, MS
and spinal cord injury.
For more information, please visit the Company’s website
at: www.acorda.com.
AMPYRA (dalfampridine) Important Safety Information
Do not take AMPYRA if you
• have ever had a seizure,
• have certain types of kidney problems, or
• are allergic to dalfampridine (4-aminopyridine), the active
ingredient in AMPYRA.
Take AMPYRA exactly as prescribed by your doctor.
Before taking AMPYRA, tell your doctor if you
• have kidney problems or any other medical conditions
• are taking compounded 4-aminopyridine
• are pregnant or plan to become pregnant. It is not known if
AMPYRA will harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if
AMPYRA passes into your breast milk. You and your doctor should
decide if you will take AMPYRA or breastfeed. You should not do
both.
• are taking any other medicines.
Stop taking AMPYRA and call your doctor right away if you have a
seizure while taking AMPYRA. You could have a seizure even if you
never had a seizure before. Your chance of having a seizure is
higher if you take too much AMPYRA or if your kidneys have a mild
decrease of function, which is common after age 50. Your doctor may
do a blood test to check how well your kidneys are working before
you start AMPYRA.
AMPYRA should not be taken with other forms of 4-aminopyridine
(4-AP, fampridine), since the active ingredient is the same.
AMPYRA may cause serious side effects, including
• severe allergic reactions. Stop taking AMPYRA and call your
doctor right away or get emergency medical help if you have
shortness of breath or trouble breathing, swelling of your throat
or tongue, or hives;
• kidney or bladder infections.
The most common adverse events for AMPYRA in MS patients were
urinary tract infection, trouble sleeping, dizziness, headache,
nausea, weakness, back pain, problems with balance, multiple
sclerosis relapse, burning, tingling, or itching of your skin,
irritation in your nose and throat, constipation, indigestion, and
pain in your throat.
Please see the Patient Medication Guide at
https://ampyra.com/medication-guide.pdf.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit http://www.fda.gov/MedWatch,
or call 1-800-FDA-1088.
Forward Looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements, other than statements of historical facts,
regarding management's expectations, beliefs, goals, plans or
prospects should be considered forward-looking. These statements
are subject to risks and uncertainties that could cause actual
results to differ materially, including the ability to realize the
benefits anticipated from the Civitas transaction and to
successfully integrate Civitas' operations into our operations; our
ability to successfully market and sell Ampyra in the U.S.; third
party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or
at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results
from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz, or any other
acquired or in-licensed programs; we may not be able to complete
development of, obtain regulatory approval for, or successfully
market CVT-301, Plumiaz, or any other products under development;
we may need to raise additional funds to finance our expanded
operations and may not be able to do so on acceptable terms; the
occurrence of adverse safety events with our products; delays in
obtaining or failure to obtain regulatory approval of or to
successfully market Fampyra outside of the U.S. and our dependence
on our collaboration partner Biogen in connection therewith;
competition; failure to protect our intellectual property, to
defend against the intellectual property claims of others or to
obtain third party intellectual property licenses needed for the
commercialization of our products; and, failure to comply with
regulatory requirements could result in adverse action by
regulatory agencies.
These and other risks are described in greater detail in Acorda
Therapeutics' filings with the Securities and Exchange Commission.
Acorda may not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this release are made only as of the date hereof, and Acorda
disclaims any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this release.
Acorda TherapeuticsJeff Macdonald,
914-326-5232jmacdonald@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Sep 2023 to Sep 2024